ipamorelin cjc 1295 troche CJC-1295 (NO DAC) + – Research Peptide Ipamorelin + CJC-1295 (No DAC)

Get In Touch Have questions about Ipamorelin products or research-use details

The peak GH concentration occurs after the peak plasma concentration of ipamorelin

Serious adverse events are rare but include pituitary axis suppression with long-term high-dose use and worsening insulin resistance in patients with pre-existing glucose issues

Dosing Approach: Many individuals remain at their initial dose for extended periods without increasing, focusing on consistency and tolerance rather than escalation

Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide